{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:32:07Z","timestamp":1783027927767,"version":"3.54.6"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T\u2010cell re\u2010directional therapies, including chimeric antigen receptor (CAR)\u2010T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR\u2010T therapy recently approved in Australia. In this clinical perspective, we describe the development of CAR\u2010T and BsA therapies, highlighting the clinical benefits and risks, together with the significant costs and infrastructure support required for the provision of these therapies to myeloma patients.<\/jats:p>","DOI":"10.1111\/imj.16647","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:49:04Z","timestamp":1740548944000},"page":"714-721","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A new era in myeloma: the advent of chimeric antigen receptor\u2010T (CAR\u2010T) cells and bispecific antibodies"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"first","affiliation":[{"name":"Royal Prince Alfred Hospital Institute of Haematology  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Li","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital Institute of Haematology  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"Australia and New Zealand Myeloma and Related Diseases Registry (ANZMRDR).Data provided by personal communication A. Spencer 2024.https:\/\/www.mrdr.net.au."},{"key":"e_1_2_14_3_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program.Cancer Stat Facts: Multiple Myeloma (2014\u20132020)[cited 2024 Sept 5]. Available from URL:https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50129"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.12.002"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_14_8_1","first-page":"1","article-title":"Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma","volume":"18","author":"Bal S","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01170-7"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00254-w"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157547"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7504"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178933"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133471"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182130"},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","unstructured":"RascheL SchinkeC TouzeauC MinnemaMC van deDonkN Rodriguez\u2010OteroP et al.Long\u2010term efficacy and safety results from the phase 1\/2 monumental\u20101 study of talquetamab a GPRC5D\u00d7CD3 bispecific antibody in patients with relapsed\/refractory multiple myeloma. EHA 2024 (Hemasphere); 2024; P915.","DOI":"10.1016\/S2152-2650(24)00976-5"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.266841"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:05:00Z","timestamp":1747238700000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/imj.16647"],"URL":"https:\/\/doi.org\/10.1111\/imj.16647","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"2024-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}